Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.